Compare Neurocrine Biosciences Inc (NBIX) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Global X SuperDividend ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Global X SuperDividend ETF trades at $24.87. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | SDIV | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $180.55 | $26.34 |
52-Week Low | $123.10 | $22.90 |
Enterprise Value | $16.49B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
